Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VarilrixTM · 1 trial · 1 indication
Vaccine response was defined as: for initially seropositive subjects, an antibody titer at Month 8 post-transplantation above or equal to (≥) 4 fold the pre-vaccination antibody titer.
Antibody titers were measured by Indirect Immunofluorescence Assay (IFA) and presented as geometric mean titers (GMTs).
| Arm | Type | Description |
|---|---|---|
| Varilrix Group | EXPERIMENTAL | Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation. |
| Name | Type | Description |
|---|---|---|
| VarilrixTM | BIOLOGICAL | Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm. |
Inclusion Criteria: Screening phase: * A male or female ≥ 18 years of age at the time of study entry. * Written informed consent obtained from the subject prior to study entry. * Patients who are planned to undergo autologous peripheral stem cell/ bone marrow transplantation. * Subjects who the in...
Varilrix is a live attenuated varicella vaccine developed by GSK plc for the prevention of varicella, commonly known as chickenpox. It is intended for use in adults aged 18 years and older. The vaccine is currently in clinical development and is not yet approved for marketing.
Varilrix is developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The vaccine is being studied for the prevention of varicella in adults. GSK is conducting clinical trials to evaluate its safety and immunogenicity.
Varilrix is in Phase 2 clinical development. A Phase 2 trial has been completed to evaluate the immunogenicity and safety of the vaccine in adults. The vaccine is investigational and has not received regulatory approval for use in any country.
Varilrix has one completed Phase 2 clinical trial registered as NCT00792623. This study, titled 'Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM),' enrolled 45 participants in Australia. The trial was uncontrolled and not randomized or double-blinded.
Yes, Varilrix is the same as VARILRIXTM. The vaccine is referred to by both names in clinical trial documentation. The Phase 2 study NCT00792623 uses the name VARILRIXTM in its title, while Varilrix is the common name for the product.